FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial
David Malka, Eric François, Frédérique Penault-Llorca, Florence Castan, Olivier Bouché, Jaafar Bennouna, François Ghiringhelli, Christelle de la Fouchardière, Christophe Borg, Emmanuelle Samalin, Jean Baptiste Bachet, Jean Luc Raoul, Laurent Miglianico, Leila Bengrine-Lefèvre, Laetitia Dahan, Cédric Lecaille, Thomas Aparicio, Trevor Stanbury, Hervé Perrier, Anne CayrePierre Laurent-Puig, Sophie Gourgou, Jean François Emile, Julien Taïeb
Research output: Contribution to journal › Article › peer-review
33Scopus
citations
Fingerprint
Dive into the research topics of 'FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial'. Together they form a unique fingerprint.